Iovance Biotherapeutics, Inc. Stock News

The U.S. FDA placed a clinical hold on Iovance's study evaluating LN-145 TIL in treating non-small-cell lung cancer. This clinical hold came after a patient in the study died.

Iovance Biotherapeutics (NASDAQ:IOVA) shares plunged after it revealed that the FDA has imposed a clinical hold on its lung cancer therapy trial following the death of a patient. The patient's death i

Iovance Biotherapeutics Inc (NASDAQ:IOVA) was last seen 17.8% lower to trade at $7.31, one of the worst stock's on the Nasdaq today.

Iovance Biotherapeutics Inc.'s stock IOVA, +6.59% fell 22.6% in premarket trading on Wednesday after the cancer therapy company said the U.S. Food and Drug Administration placed a clinical hold on its

Iovance Biotherapeutics (NASDAQ: IOVA) stock price suffered a harsh reversal on Wednesday after the company suffered a major setback. The stock, which has been in a strong uptrend, crashed by more tha

The FDA places a clinical hold on Iovance's trial of a lung cancer therapy after the company reports a death potentially related to the treatment.

Iovance Biotherapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its trial on a therapy for a type of lung cancer.

IOVA's marketing application for lifileucel is still awaiting approval from the FDA, with a new decision date set for February 24, 2024. Despite the delay, IOVA suggests a possible early approval in J

Small to mid-cap biotechs are known for their extreme volatility, and sometimes, market-crushing returns on capital. Iovance Biotherapeutics and Viking Therapeutics are two of the most popular stocks

Wall Street analysts following Iovance Biotherapeutics set price targets that suggest the stock can triple your money in 2024. Iovance Biotherapeutics is developing cell-based cancer therapies, and th

In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny

Goldman Sachs initiated a buy recommendation on Iovance with a $12 price target. Many on Wall Street like the stock because of the potential near-term approval of its promising melanoma drug.

Biotech stocks are slumping yet again today. However, Iovance Biotherapeutics is swimming against the current thanks to excitement over its adoptive cell therapy.

Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.